|Bid||5.86 x 900|
|Ask||5.94 x 1300|
|Day's Range||5.66 - 6.14|
|52 Week Range||2.75 - 12.50|
|Beta (3Y Monthly)||5.43|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 9, 2017 - Aug 14, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||16.30|
HENDERSON, NV / ACCESSWIRE / March 22, 2019 / Many high-profile companies in the cannabis market have posted incredible gains since start of 2019 and this trend looks to continue. The race to profit from ...
CORAL GABLES, FL / ACCESSWIRE / March 20, 2019 / The marijuana stock market has exhibited great promise in the month of March, resulting in the excitement surrounding the cannabis industry. As we look to the future, these smaller companies may play a role in securing potential opportunities for the cannabis industry. ParcelPal Technology Inc (PTNYF) (PKG), Curaleaf Holdings Inc (CURLF) (CURA.CN), Zynerba Pharmaceuticals Inc (ZYNE), and GW Pharmaceuticals plc (GWPH) represent 4 marijuana stocks getting a boost from today's headlines.
The cannabis market is buzzing right now. But the recent rally in cannabis stocks has left some of the bigger names looking overvalued. For example Aurora Cannabis (ACB) - which has doubled year-to-date, is now facing a downside risk of 8% according to the Street. So with that in mind we focused in on stocks that still have massive upside potential ahead. We used TipRanks to focus in on the latest ratings from analysts with the strongest stock picking track record. Without further ado, here are three of the best cannabis stocks to be looking at right now:Aphria Has More Room to RunOver the last three years, Aphria (APHA) shares have exploded by over 850%, and according to the Street significant further upside potential lies ahead.That’s despite a horrendous 2018, which featured a hostile takeover attempt, the exit of its CEO and allegations from a short-seller that insiders profited from acquiring international businesses at highly inflated prices. This was the central accusation of a short report that roiled the stock price, and renewed concerns about the company’s corporate governance.Luckily the most serious allegations have now been refuted. A special board committee found that the price paid for businesses in Latin America was acceptable and that these assets are now progressing according to plan. And with newly-appointed chairman Irwin Simon now acting as CEO, short-seller Quintessential is appeased, tweeting: “With a new management team the company has a chance to a brighter future and we are accordingly moving on to new projects.” Simon is the founder, and former CEO of multi-billion company Hain Celestial Group.In short, this low-cost cannabis producer is ready to rebound. This is reflected by recent ratings from the Street. Most notably, top-rated Clarus analyst Noel Atkinson has just reiterated his buy rating on APHA with a price target of $19.25. This translates into sizeable upside potential of over 85% from the stock’s current share price of $9.63. (To watch Atkinson's track record, click here)According to Atkinson the company needs to stop looking back and start executing to move the ball forward. He believes Aphria’s list of near-term operational milestones is significant, and successful execution could transform the company both in terms of financial results and investor sentiment. “If management can execute, there is the potential for a very substantial re-rating of the stock price from current levels” the analyst tells investors.Overall, Wall Street’s confidence backing this cannabis stock is strong, with TipRanks analytics showcasing APHA as a Strong Buy. Based on 6 analysts polled in the last 3 months, 5 are bullish on Aphria stock, while only 1 remains sidelined. The 12-month average price target stands at $15.33, marking over 50% upside from where the stock is currently trading. (See APHA's price targets and analyst ratings on TipRanks)Zynerba Stock Looks Less FragileZynerba (ZYNE) focuses on transdermal cannabinoid therapeutics. Its goal is to improve the lives of patients affected by rare neuropsychiatric conditions including Fragile X syndrome and autism spectrum disorder. Currently the company is trialing a groundbreaking cannabinoid (CBD) gel. This is the first and only patented permeation-enhanced CBD gel for delivery through the skin and into the circulatory system.According to ZYNE, the gel offers multiple advantages when compared to the more traditional oral delivery. By skipping the digestive process, ZYNE can minimize psychoactive effects, limit drug-drug interaction, and avoid digestion of the drug by the liver.And for investors, now’s the time to start taking a closer look at Zynerba’s investing potential. That’s because this cannabis biotech is gearing up for a transformational 2019 according to five-star HC Wainwright analyst Oren Livnat. Today, Livnat reiterated his buy rating on ZYNE with a $23 price target, which indicates jaw-dropping upside of over 350%. (To watch Livnat's track record, click here)The key data to look out for comes from Zynerba’s lead Fragile X (FXS) program. ZYNE continues to enroll patients for the pivotal Phase 3 study (CONNECT-FX), and the all-important data is expected in 2H19. Livnat is optimistic for positive data, although he admits that this is a risky call given other companies’ failure in this indication.Livnat noted, "We reiterate our Buy, rating and see the current $105M market cap ($27M EV) leaving remarkable upside potential on positive data; as our $23 price target still reflects only a 35% probability of success in FXS.”Overall, this cannabis-related player stands as a 'Strong Buy' name among Wall Street analysts. In the last 12 months, ZYNE stock has won four 'buy' ratings vs. only one 'hold' rating. With a return potential of over 300%, the stock's consensus price target lands at $20. (See ZYNE's price targets and analyst ratings on TipRanks)Arena Stock Falls Under the RadarHere we have a promising biotech that is currently under-the-radar for most investors. Unlike Zynerba, Arena (ARNA) devotes some of its pipeline to CBD therapeutics, while also devoting some of its pipeline to non-cannabinoid medicine.This means that even though its most advanced drug currently in trial is Etrasimod (for colitis, Crohn’s and atopic dermatitis), for cannabis investors Olorinab is the key focus. Also known as APD371, Olorinab is an oral agonist of cannabinoid receptor 2 (CB2), which is part of the natural cannabinoid receptor system found in our bodies. The drug is designed to treat pain associated with gastrointestinal diseases like IBS and Crohn’s- a large and growing market.And the best part is that these drugs could ultimately reduce the need for highly addictive opioid medications. As Bruce Yacyshyn, medical director at UC Health University Hospital, says: “There is a strong clinical need for non-opiate treatments for the management of chronic abdominal pain in patients with gastrointestinal disorders, including Crohn’s disease, ulcerative colitis and irritable bowel syndrome.”As for the timeline, Olorinab Phase 2 trial in IBS pain is expected to begin in 2H19. Cantor Fitzgerald’s Alethia Young is keeping a close eye on these developments, writing “Over the next 12-18 months, we see opportunities like olorinab and etrasimod expansion as underappreciated at current levels. With many Ph2 and 3 trials reading out in 2020, we expect investors to take note, and we see little downside risk in the interim.”She reiterates her buy rating on Arena with a $62 price target- indicating 33% upside potential from current levels. Alongside Young, Needham’s Alan Carr is the only other top analyst who has published a recent rating on Arena. He also rates the stock a Buy, writing “we think olorinab remains an unappreciated potential opportunity with commercial synergies with etrasimod.”To read more on the nitty gritty of what’s going on in the rising cannabis industry, click here. More recent articles from Smarter Analyst: * Will New Streaming Service Propel Apple (AAPL) Stock to New Heights? * Analyst Commends Cannabis Stock Aurora (ACB) for Peltz Pick * This Cannabis Stock Just Got a Huge Vote of Confidence * Apple's (AAPL) Streaming Video Buzz: Should You Buy the Hype?
Phase 3 VANISH program underway, evaluating oral ibrexafungerp for the treatment of acute VVC; anticipate top-line data in the first half of 2020 with NDA submission in the second half of 2020 Oral ibrexafungerp ...
The Devon, Pennsylvania-based company said it had a loss of 44 cents per share. The specialty pharmaceutical company posted revenue of $86,000 in the period. For the year, the company reported that its ...
DEVON, Pa., March 11, 2019 -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and.
Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that it has initiated the Phase 2 BRIGHT (An Open-Label Tolerability and Efficacy Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with Autism Spectrum Disorder) trial. The trial will assess the safety, tolerability and efficacy of Zygel (previously referred to as ZYN002) for the treatment of child and adolescent patients with Autism Spectrum Disorder (ASD). The Company expects to present topline data from this study in the first half of 2020.
Although the majority of U.S.-based cannabis companies and many foreign ADRs trade over-the-counter, a few marijuana companies are traded on the NASDAQ. Some investors prefer stocks that are listed on the NASDAQ to other exchanges due to their increased liquidity and tighter spreads than the OTC markets.
Armando Anido became the CEO of Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) in 2014. First, this article will compare CEO compensation with compensation at similar sized companies. Next, we'll consider growth thatRead More...
Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE ) shares were advancing Tuesday after the company notched a new U.S. patent for its cannabidiol product candidate, ZYN002 transdermal gel. What Happened The biotech, ...
Premier Health Group (PHGRF) (PHGI), Heat Biologics Inc (HTBX), Zynerba Pharmaceuticals Inc (ZYNE), and Aurora Cannabis Inc (ACB) represent 4 healthcare stocks to keep on your radar this week. Premier Health Group (PHGRF) (PHGI) today announced plans to expand its development team at Cloud Practice Inc. to support the Company's focus on digitizing health care. The Company recently hired four new full-time employees, three Web Software Developers and one User Interface/User Experience (UI/UX) Designer, to support the build-out of its patient-centric platform and mobile app - a beta version of which will be available by end of Q2.
Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the U.S. Patent and Trademark Office has issued US Patent No. 10,213,390, titled “Treatment of Fragile X Syndrome with Cannabidiol” which includes claims directed to methods of treating Fragile X Syndrome by administering a therapeutically effective amount of synthetic or purified cannabidiol. This new patent, which expires in 2038, is part of an expanding intellectual property portfolio covering the Company's cannabidiol (CBD) product candidate, ZYN002 Transdermal CBD gel.
Shares of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) — which specializes in developing transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders — were trading in the green Thursday. The pharmaceutical company conducted a study that showed that cannabidiol (CBD) can be an effective treatment for osteoarthrits patients. The study showed that patients can be administered between 250 mg and 500 mg of CBD, although in some cases, the effective amount could be as low as 125 mg. Using a gel gives the advantage of allowing the CBD to be absorbed through the skin directly in the bloodstream and avoiding first-pass liver metabolism, which allows lower dosages of active phramceutical ingredients.
Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the appointment of Pamela Stephenson to its Board of Directors. “We are excited to welcome Pamela to our Board at such a pivotal time for the Company,” said Armando Anido, Chairman and Chief Executive Officer of Zynerba. “Pamela brings with her a wealth of expertise in commercial planning, market development, product launch and market access.
HENDERSON, NV / ACCESSWIRE / February 13, 2019 / When looking for great growth opportunities to invest in, look no further than the healthcare sector. Healthcare stocks have consistently produced big winners ...
HENDERSON, NV / ACCESSWIRE / February 11, 2019 / Investing in biotech companies can provide investors with huge gains. With that in mind, we're highlighting a few you should know about. One you should ...
Lately, the pharmaceutical companies are trying to use cannabis-based therapies to treat all sorts of medical conditions. Zynerba (NASDAQ:ZYNE) is another contender in this increasingly-crowded field. Whether that's a good or bad thing for Zynerba stock remains to be seen.After all, they appear to have a pretty interesting play within the space. Their ZYN002 drug candidate is, according to the company, "the first and only pharmaceutically-produced CBD formulated as a permeation‑enhanced gel for transdermal delivery".They are running studies on this CBD gel for a variety of conditions. They are investigating treatments for Fragile X, Tourette's, and seizures, among other conditions.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Monster Growth Stocks to Buy for 2019 and Beyond Understanding The Fragile X Syndrome Therapeutic LandscapeFragile X Syndrome is a relatively rare condition occurring in roughly 1 out of every 4,000 boys and 1 out of every 8,000 girls. Researchers believe that the condition is caused by a DNA defect. Fragile X often presents symptoms in children by age 2 including intellectual disability and physical characteristics such as long face and a prominent jaw.It is sometimes a complicated diagnosis as Fragile X can look like other developmental disorders. Many Fragile X children have Attention Deficit Disorder. Additionally, many exhibit features of autism disorders. Furthermore, a significant number of Fragile X patients have frequent seizures.This leads to an interesting position for Zynerba. The company states that there are no approved drug therapies for Fragile X. However, it notes that doctors use various drugs off-label to treat various Fragile X symptoms. That makes sense, as there are treatments for things such as seizures.Directly, as far as competition, Zynerba notes that Neuren Pharmaceuticals, Ovid Therapeutics (NASDAQ:OVID) and Marinus Pharmaceuticals (NASDAQ:MRNS) are all active in the research space seeking a treatment directly for Fragile X syndrome.That's not all. Zynerba has focused on the treatment of seizures in particular. Within that particular space, it faces cannabinoid-based competition on several fronts. GW Pharma (NASDAQ:GWPH), with its more than $4 billion market cap, is targeting this space and is widely thought of as a leader in cannabinoid research.Additionally, Insys (NASDAQ:INSY) is researching CBDs for seizures and infantile spasms as well. So, should Zynerba's ZYN002 be a clinical success, it won't necessarily be the first or best therapy that reaches the market. Why Zynerba Stock Popped RecentlyOn January 28th, Zynerba stock shot up 30% to reach $4.80. In subsequent days, it rallied further, reaching as high as the $6 mark. What happened on Jan. 28 that set the rally in motion? There doesn't appear to be much in the way of hard news, but the company did give a high-profile presentation and it appears this set investor enthusiasm in motion.In this presentation, the company confirmed that things are moving along as planned for its combination Phase 2/3 CONNECT trail for Fragile X syndrome. Zynerba also expects to release results for its Phase 2 trial for developmental and epileptic encephalopathies in the latter half of 2019.To add to that, Zynerba remains in reasonably strong financial position. The company reported $59.8 million in cash as of December 31st, 2018.Given its current burn rate, that should give Zynerba funds to continue its current research through the second half of 2020. While Zynerba will have to raise more funds at some point, it still has plenty of time to deliver its crucial trial results later in 2019 before going back to the market for more money. The CBD FactorIt's difficult to consider ZYNE stock without thinking about the X factor here: investor enthusiasm for marijuana-related stocks. Since late December the Alternative Harvest (NYSEARCA:MJ) marijuana ETF has ripped 50% higher off the lows. Stocks like Aphria (NYSE:APHA) and Canopy Growth (NYSE:CGC) are soaring almost every day.Zynerba itself hadn't participated in this enthusiasm, at least not until recently. However, that may be changing. Recently, famous TV host Jim Cramer talked up so-called "marijuana-adjacent" biotech firms as stocks with big potential in 2019.Cramer said:"These are not pot companies. They are drug companies focused on developing artificial cannabinoids that mimic what cannabis does to your body […] As we get more and more data showing the efficacy of medicinal marijuana, I think more investors will embrace actual medicines that do the same thing as marijuana, but they do it more reliably."With ZYNE stock, you are getting a call option on this thesis playing out later in 2019. Zynerba Stock VerdictI rarely invest in clinical stage biotech companies. It's a difficult industry; far more companies fail than succeed. Be careful with these sorts of stocks and don't invest more than you can afford to lose.That said, Zynerba has an interesting drug candidate, and is certainly positioned in a hot sector of the market. With plenty of cash to make it into mid-2020, and key data coming before then, ZYNE stock has plenty of speculative value for active traders.One upcoming catalyst to watch out for. On February 11th, CEO Armando Anido will be giving a presentation at the 2019 BIO CEO and Investor Conference. With ZYNE stock remaining volatile in recent days, any further data releases or business updates in this presentation could cause a big move in Zynerba shares.At the time of this writing, Ian Bezek held no positions in any of the aforementioned securities. You can reach him on Twitter at @irbezek. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * Are These 7 Dividend Aristocrats ETFs Fit for a King? * 7 of the Best Emerging Markets Stocks to Buy * 5 Gold Stocks That Should Glitter in 2019 Compare Brokers The post Zynerba Stock Is Marijuana-Adjacent Play Worth a Look appeared first on InvestorPlace.
Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido will present a company overview at the 2019 BIO CEO and Investor conference. The presentation will take place on Monday, February 11, 2019 at 2:00 PM EST at the New York Marriott Marquis. A live webcast of the presentation will be accessible on the Investor Relations page of http://www.zynerba.com.
HENDERSON, NV / ACCESSWIRE / February 4, 2019 / A rough end to 2018 left a host of biotech companies oversold. Many of these companies are starting to rally, and now is the time to research them before ...
HENDERSON, NV / ACCESSWIRE / February 1, 2019 / The biotechnology world is a buzz, 2018's oversold, underperformers are 2019's discounted gems. Below are several biotech stocks that could make you big ...
HENDERSON, NV / ACCESSWIRE / January 30, 2019 / The biotechnology sector has been roaring back strong in 2019. There a few companies that we think you should be researching right now. One company who's ...
NEW YORK, NY / ACCESSWIRE / January 30, 2019 / U.S. markets were mostly down Tuesday on the latest batch of corporate earnings and as investors await details from the Feds' two-day policy meeting. The ...